loadpatents
Patent applications and USPTO patent grants for Brannetti; Barbara.The latest application filed is for "cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell".
Patent | Date |
---|---|
Cd20 Therapies, Cd22 Therapies, And Combination Therapies With A Cd19 Chimeric Antigen Receptor (car)- Expressing Cell App 20220195010 - Bitter; Hans ;   et al. | 2022-06-23 |
Method Of Detecting Tim-3 Using Antibody Molecules To Tim-3 App 20220185883 - Sabatos-Peyton; Catherine Anne ;   et al. | 2022-06-16 |
Combination Therapies Comprising Antibody Molecules To Tim-3 App 20220133889 - Dranoff; Glenn ;   et al. | 2022-05-05 |
Il-18 Binding Molecules App 20220098296 - BARDROFF; Michael Otto ;   et al. | 2022-03-31 |
Method of detecting TIM-3 using antibody molecules to TIM-3 Grant 11,155,620 - Sabatos-Peyton , et al. October 26, 2 | 2021-10-26 |
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Grant 11,149,076 - Bitter , et al. October 19, 2 | 2021-10-19 |
IL-18 binding molecules Grant 11,111,293 - Bardroff , et al. September 7, 2 | 2021-09-07 |
Immune-stimulating Humanized Monoclonal Antibodies Against Human Interleukin-2, And Fusion Proteins Thereof App 20210246200 - Arenas-Ramirez; Natalia ;   et al. | 2021-08-12 |
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain Grant 11,026,976 - Brannetti , et al. June 8, 2 | 2021-06-08 |
Antibody molecules to TIM-3 and uses thereof Grant 10,981,990 - Sabatos-Peyton , et al. April 20, 2 | 2021-04-20 |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof Grant 10,889,643 - Arenas-Ramirez , et al. January 12, 2 | 2021-01-12 |
Nucleic acids encoding anti-Factor P antibodies Grant 10,865,237 - Johnson , et al. December 15, 2 | 2020-12-15 |
Antibody Molecules To Tim-3 And Uses Thereof App 20200308277 - Sabatos-Peyton; Catherine Anne ;   et al. | 2020-10-01 |
Antibody Molecules To Tim-3 And Uses Thereof App 20200223917 - Sabatos-Peyton; Catherine Anne ;   et al. | 2020-07-16 |
Nucleic Acid Molecules Encoding Chimeric Antigen Receptors Comprising A Cd20 Binding Domain App 20200113941 - Brannetti; Barbara ;   et al. | 2020-04-16 |
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain Grant 10,525,083 - Brannetti , et al. J | 2020-01-07 |
Antibody molecules to TIM-3 and uses thereof Grant 10,472,419 - Sabatos-Peyton , et al. Nov | 2019-11-12 |
Cd20 Therapies, Cd22 Therapies, And Combination Therapies With A Cd19 Chimeric Antigen Receptor (car)- Expressing Cell App 20190292238 - Bitter; Hans ;   et al. | 2019-09-26 |
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Grant 10,253,086 - Bitter , et al. | 2019-04-09 |
Il-18 Binding Molecules App 20190085068 - BARDROFF; Michael Otto ;   et al. | 2019-03-21 |
Immune-stimulating Humanized Monoclonal Antibodies Against Human Interleukin-2, And Fusion Proteins Thereof App 20190016797 - Arenas-Ramirez; Natalia ;   et al. | 2019-01-17 |
Compositions And Methods For Antibodies Targeting Factor P App 20180327486 - JOHNSON; Leslie Ngozi Anuna ;   et al. | 2018-11-15 |
IL-18 binding molecules Grant 10,081,677 - Bardroff , et al. September 25, 2 | 2018-09-25 |
Combination Therapies Comprising Antibody Molecules To Tim-3 App 20180207273 - Dranoff; Glenn ;   et al. | 2018-07-26 |
Compositions comprising antibodies targeting factor P Grant 9,988,440 - Johnson , et al. June 5, 2 | 2018-06-05 |
Treatment Of Cancer Using Chimeric Antigen Receptors App 20180125892 - Brannetti; Barbara ;   et al. | 2018-05-10 |
Antibody molecules to TIM-3 and uses thereof Grant 9,884,913 - Sabatos-Peyton , et al. February 6, 2 | 2018-02-06 |
Antibody Molecules To Tim-3 And Uses Thereof App 20170198041 - Sabatos-Peyton; Catherine Anne ;   et al. | 2017-07-13 |
Antibody Molecules To Tim-3 And Uses Thereof App 20170190777 - Sabatos-Peyton; Catherine Anne ;   et al. | 2017-07-06 |
Antibody molecules to TIM-3 and uses thereof Grant 9,605,070 - Sabatos-Peyton , et al. March 28, 2 | 2017-03-28 |
IL-18 binding molecules App 20160376361 - Bardroff; Michael Otto ;   et al. | 2016-12-29 |
Cd20 Therapies, Cd22 Therapies, And Combination Therapies With A Cd19 Chimeric Antigen Receptor (car)- Expressing Cell App 20160362472 - Bitter; Hans ;   et al. | 2016-12-15 |
IL-18 binding molecules Grant 9,376,489 - Bardroff , et al. June 28, 2 | 2016-06-28 |
Antibody Molecules To Tim-3 And Uses Thereof App 20150218274 - Sabatos-Peyton; Catherine Anne ;   et al. | 2015-08-06 |
Compositions And Methods For Antibodies Targeting Factor P App 20150158936 - Johnson; Leslie Ngozi Anuna ;   et al. | 2015-06-11 |
Antibodies that bind factor P Grant 9,051,365 - Johnson , et al. June 9, 2 | 2015-06-09 |
IL-18 binding molecules App 20140112915 - Bardroff; Michael Otto ;   et al. | 2014-04-24 |
Compositions And Methods For Antibodies Targeting Factor P App 20130295102 - Johnson; Leslie Ngozi Anuna ;   et al. | 2013-11-07 |
Fibronectin-based Binding Molecules And Their Use App 20100322930 - Kolbinger; Frank ;   et al. | 2010-12-23 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.